| abstract |
An imidazolidine compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof wherein R1is H, C1-C6alkyl, C2-C6alkenyl or C2-C6alkynyl each of which may be substituted with a cyano group or with one or more halogen groups; R2ais H, phosphoric ester or derivative thereof or a carboxylic ester, preferably P(O)(OH)2, C(=O)— (CH2)2-CO2H, C(=O)CH(NH3Cl)iPr or S(O)2(OH); R2bis H; R2cis H or C1-C6alkyl; R3is a halogen, cyano or a C1-C6alkyl which may be substituted with a halogen group; R4is a halogen, cyano, nitro or C1-C6alkyl which may be substituted by one or more halogen groups; m is 0, 1 or 2 and n is 1, 2 or 3. Such imidazolidine compounds are useful in the treatment of androgen receptor conditions, for example, cachexia. |